Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for bone mineral density studies, effective May 15, 2026. Here's what billing teams need to know before that date.
This update touches one of the more routinely billed diagnostic categories in primary care, endocrinology, rheumatology, and women's health. The CMS bone mineral density studies coverage policy governs when Medicare will pay for bone densitometry — and changes here have direct reimbursement consequences at scale. The policy document does not list specific CPT or HCPCS codes in the data available at publication time; check the full policy source for code-level detail as it becomes available.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Bone (Mineral) Density Studies |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Primary care, endocrinology, rheumatology, obstetrics & gynecology, orthopedics, geriatrics |
| Key Action | Audit your bone densitometry billing workflows and documentation templates before May 15, 2026 |
CMS Bone Mineral Density Study Coverage Criteria and Medical Necessity Requirements 2026
The CMS bone mineral density studies coverage policy sits within the broader Medicare framework governing which beneficiaries qualify for covered bone densitometry. Medical necessity is the central gating factor. Medicare does not pay for bone density testing on demand — it pays when documented clinical criteria are met.
Under longstanding Medicare policy, bone density studies are covered for specific at-risk populations. These include estrogen-deficient women at clinical risk for osteoporosis, individuals with vertebral abnormalities, patients receiving or being considered for long-term glucocorticoid therapy, patients with primary hyperparathyroidism, and individuals being monitored to assess the response to or efficacy of an approved osteoporosis drug therapy. Each of these groups has its own documentation requirements.
The medical necessity standard here is not vague. Your documentation needs to show which qualifying condition applies to the patient. A claim that lacks a clear link between the patient's diagnosis and one of these covered indications is a claim that is exposed to denial.
Prior authorization is not typically required by Medicare for bone density studies when covered under the national benefit — but do not assume that means documentation doesn't matter. Medicare Administrative Contractors routinely audit bone densitometry claims, and insufficient documentation produces the same financial result as a prior authorization failure. You don't get paid.
One area billing teams consistently get wrong: frequency. Medicare generally covers bone density studies once every two years (24 months) for most qualifying patients. Monitoring situations — such as tracking response to osteoporosis therapy — may allow for different intervals, but those require clear clinical justification in the record. Billing outside the covered frequency without documented clinical rationale is a direct path to claim denial.
Because the full detail of this May 2026 modification is not yet available in the policy data at publication, the exact nature of the change is not confirmed here. What is clear is that a modification occurred, it carries a May 15, 2026 effective date, and your team needs to know what shifted before that date hits. If you handle meaningful Medicare volume in any of the affected specialties, talk to your compliance officer now — not after the effective date.
CMS Bone Mineral Density Study Exclusions and Non-Covered Indications
Not every bone density scan is a covered scan under Medicare. The coverage policy is narrow by design. Screening without a qualifying clinical indication is not covered. General population screening — the kind a patient requests because they read an article — does not meet medical necessity under this policy.
Repeat studies within the 24-month frequency window are not covered unless the clinical situation genuinely warrants an exception and that exception is documented in advance. Claims that simply appear before the 24-month mark without supporting documentation will be denied.
Bone density testing performed solely for research purposes, or in settings that don't meet Medicare's facility and equipment standards, also falls outside covered indications. If your practice uses portable or peripheral devices — like peripheral DXA, quantitative ultrasound of the heel, or single-energy X-ray absorptiometry — be aware that coverage rules for these technologies differ from central DXA. The coverage policy distinctions between central and peripheral measurement technologies have been a recurring source of billing confusion, and they remain relevant here.
Coverage Indications at a Glance
Because the specific policy modification data is not fully available at publication, the table below reflects the established Medicare bone density coverage framework. Verify all indications against the updated policy document at the effective date of May 15, 2026.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Estrogen-deficient woman at clinical risk for osteoporosis | Covered | Codes not listed in current policy data | Clinical risk documentation required |
| Vertebral abnormalities identified on imaging | Covered | Codes not listed in current policy data | Must be documented by treating provider |
| Long-term glucocorticoid (steroid) therapy — current or planned | Covered | Codes not listed in current policy data | Document duration and dose |
| Primary hyperparathyroidism | Covered | Codes not listed in current policy data | Diagnosis must support medical necessity |
| Monitoring response to osteoporosis drug therapy | Covered | Codes not listed in current policy data | Frequency rules apply; document clinical rationale |
| General population screening without qualifying indication | Not Covered | N/A | Does not meet medical necessity |
| Repeat study within 24-month window without clinical exception | Not Covered | N/A | Document exception before billing |
| Peripheral/portable device studies (e.g., heel QUS, pDXA) | Coverage varies | Codes not listed in current policy data | Confirm with your MAC; technology-specific rules apply |
CMS Bone Mineral Density Billing Guidelines and Action Items 2026
Here's what your billing team should do before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the updated policy now. Go to the source document and read the modification directly. Do not rely on your current workflows until you know exactly what changed. A "modified" designation means something in the criteria, frequency rules, documentation requirements, or covered indications shifted. |
| 2 | Audit your documentation templates. Every bone mineral density billing encounter needs a clear link between the patient's qualifying condition and one of Medicare's covered indications. If your intake forms or EHR templates don't capture the specific qualifying indication — not just an osteoporosis diagnosis code — fix that before the effective date. |
| 3 | Check your frequency tracking. Set up a hard stop or reporting flag for bone density studies billed within 24 months of a prior study for the same patient. This is one of the most common sources of claim denial in this category. Your practice management system should flag it before the claim goes out. |
| 4 | Review your diagnosis code pairing. Bone mineral density billing lives or dies on the specificity of the ICD-10-CM codes you submit alongside the procedure. Unspecified osteoporosis codes are weaker support than specific codes tied to risk factors, fracture history, or documented steroid use. Tighten your ICD-10 selection before May 15, 2026. |
| 5 | Confirm your MAC's local coverage determination. National Medicare policy sets the floor, but your Medicare Administrative Contractor may have a local coverage determination (LCD) that adds requirements or restrictions on top of the national policy. CMS national policy and MAC-level LCD requirements both apply — and they don't always say the same thing. Pull your MAC's current LCD on bone density and compare it to this updated national policy. |
| 6 | Alert your ordering providers. The clinical documentation that supports a covered bone density study gets written by the ordering physician, not the billing team. Your medical director or department heads in primary care, endocrinology, rheumatology, and OB/GYN need to know this policy changed. Send them a one-page summary of the covered indications and frequency rules. |
| 7 | Talk to your compliance officer if you're uncertain. If your practice bills high volumes of bone density studies, or if you serve populations with complex steroid or osteoporosis treatment histories, the financial exposure here is real. Get a compliance review of your bone densitometry billing patterns before May 15, 2026 — not after your first denial wave. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Bone Mineral Density Studies Under This Policy
The policy data available at publication does not include specific CPT, HCPCS, or ICD-10 codes. This is not unusual during the window between a policy modification announcement and full publication of the updated document.
What to do: Pull the full policy from the CMS source document directly. For bone mineral density billing, the relevant code set typically includes central DXA procedure codes, axial codes, and peripheral measurement codes — but you should verify the exact codes covered, excluded, or newly affected by this modification from the official document before the effective date of May 15, 2026.
Do not assume the code set is unchanged just because you don't have updated code data yet. A policy modification can shift which codes are covered, which require additional documentation, or which are newly excluded — without changing the codes themselves.
If you need code-level guidance before the full policy publishes, your MAC's LCD for bone density studies is the most reliable interim source. Most MACs publish explicit code lists alongside their LCDs. Cross-reference that with the updated CMS policy once it's fully available.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.